Abstract
Introduction
Driven primarily by continued uptake of Shire' s market leading ADHD drug,
Adderall XR (amphetamine extended release), seven major market ADHD revenues
grew strongly at a compound annual growth rate (200408) of 13.5% to reach
almost $4.4 billion in 2008. Ongoing uptake of Shire' s Vyvanse
(lisdexamfetamine), was also a key contributor to market growth between 2007
and 2008.
Key reasons to purchase this research
- This report gives a strategic analysis of the likely impact that recent
events will have on the future ADHD market.
- Includes sales forecasts for the key ADHD brands and generics as well as
pipeline agents in the seven major markets to 2018.
- Quantify the current and future size of the seven major ADHD markets.
Table of Contents
OVERVIEW
- This product contains forecasts for attention-deficit hyperactivity
disorder (ADHD) drugs across the seven major markets from 2009 to 2018. It has
been designed for delivery in an excel data pack format.
- The associated report can be found under Latest research in the
Knowledge centre, through the search function or by contacting your sales
representative.
- Introduction
- Scope of this research
- Research and analysis highlights
- Key reasons to read this report
- Forecasting Methodology
- The forecasting model:
- General event information:
- Event selection and quantification:
- Event parameters:
| 
